All In Biotech

Drug Trial Radar · NCT03772041

Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure

A Multicenter, Double-blind, Randomized, Active-controlled, Parallel-group, Non-inferiority Trial to Evaluate the Efficacy and Safety of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure

Last checked: Nov 20, 2026Latest source record: Aug 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 294 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

294

Actual

Start

Jan 16, 2019

Primary completion

Jul 21, 2020

Study completion Jul 29, 2020

Sponsor

Sponsor type
Industry
First posted
Dec 11, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To confirm the non-inferiority of OPC-61815 16-mg injection to tolvaptan 15-mg tablet using as the primary endpoint the change in body weight following 5-day intravenous administration of OPC-61815 16-mg injection or 5-day oral administration of tolvaptan 15-mg tablet to CHF patients with volume overload despite having received diuretics other than vasopressin antagonists

Conditions

  • Congestive Heart Failure

Interventions

  • OPC-61815Drug

    Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg

  • Tolvaptan Tab 15 MGDrug

    Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Body WeightTime frame: Baseline, Day 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Saiseikai Kumamoto Hospital

    Kumamoto, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.